Technetium-99m-HMPAO, technetium-99m-ECD and iodine-123-IMP cerebral blood flow measurements with pharmacological interventions in primates

Journal of Nuclear Medicine

Volumn 38, Issue 12, 1997, Pages 1897-1901

  Dormehl, Irene C ^a   Oliver, Douglas W ^b   Langen, Karl Josef ^b   Hugo, Niek ^b   Croft, Sandra A ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NONE

Author keywords

Baboon model; CBF SPECT; Drug tracer interaction

Indexed keywords

ACETAZOLAMIDE; CYSTEINE ETHYL ESTER TC 99M; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IOFETAMINE I 123; NIMODIPINE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BRAIN BLOOD FLOW; BRAIN SCINTISCANNING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFECT; IMAGE ANALYSIS; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ACETAZOLAMIDE; AMPHETAMINES; ANIMALS; BRAIN; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR CIRCULATION; CYSTEINE; DRUG INTERACTIONS; IODINE RADIOISOTOPES; IOFETAMINE; MALE; NIMODIPINE; ORGANOTECHNETIUM COMPOUNDS; PAPIO; RADIOPHARMACEUTICALS; SEROTONIN AGONISTS; SUMATRIPTAN; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031461261     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Winchell HS, Baldwin RM, Lin TH. Development of I-123-labeled amines for brain studies: localization of I-123 iodo-phenyalkyl amines in rat brain. J Nucl Med 1980;21:940-947.
2. 123I-iodoamphetamine (IMP) tomography. J Nucl Med 1982;23:196-203.
3. 123I)-iodo-amphetamine in human brain. J Cereb Blood Metab 1989;30:150-156.
4. Lassen NA, Henriksen L, Holm S, et al. Cerebral blood flow tomography: xenon-133 compared with isopropyl-amphetamine-iodine-123. J Nucl Med 1983;27:17-21.
5. 99mTc]-d,1-HMPAO in the human brain after intracarotid bolus injection: a kinetic analysis. J Cereb Blood Flow Metab 1988;8(suppl):S13-S22.
6. Neirinckx RD, Burke JF, Harrison RC, Forster AM, Andersen AR, Lassen A. The retention mechanism of technetium-99m-HMPAO: intracellular reaction with glutathione. J Cereb Blood Flow Metab 1988;8(suppl):S4-S12.
7. Walovitch RC, Hill TC, Garrity ST, et al. Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, part 1: pharmacology of technetium-99m ECD in non-human primates. J Nucl Med 1989;30:1892-1901.
8. Holman LB, Hellman RS, Goldsmith SJ, et al. Biodistribution, dosimetry and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. J Nucl Med 1989;30:1018-1024.
9. Vallabhajosula S, Zimmermann RE, Picard M, et al. Technetium-99m ECD: a new brain imaging agent. In vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 1989;30:599-604.
10. Huglo D, Rousseaux M, Leys D, Fialdes P, Steinling M. Regional cerebral blood flow imaging: a quantitative comparison of 99m-Tc-bicisate with 133-Xe using single photon emission computed tomography. J Cereb Blood Flow Metab 1994;14(suppl 1):S76-S83.
11. Lassen NA, Sperling B. 99m-Tc-bicisate reliably images CBF in chronic brain diseases but fails to show reflow hyperemia in subacute stroke: report of a multicenter trial of 105 cases comparing 133-Xe and 99m-Tc-bicisate (ECD, Neurolite) measured by SPECT on the same day. J Cereb Blood Flow Metab 1994;14(suppi 1):S44-S48.
12. 99mTc-ECD SPECT. J Cereb Blood Flow Metab 1994;14(suppl 1):S49-S57.
13. 123I]IMP in cortical and subcortical strokes. J Cereb Blood Flow Metab 1994;14(suppl 1):S84-S90.
14. Ahn CS, Tow DE, Yu CC, Greene RW. Effect of metabolic alterations on the accumulation of Tc-99m-labeled D,L-HMPAO in slices of rat cerebral cortex. J Cereb Blood Flow Metab 1994;14:324-331.
15. Höllerhage H-G, Gaab MR, Zumkeller M, Walter GF. Nimodipine treatment has been implicated in impaired CBF autoregulation. J Neurosurg 1988;69:919-922.
16. Holm S, Madsen PL, Sperling B, Lassen NA. Use of 99m-Tc-bicisate in activation studies by split-dose technique. J Cereb Blood Flow Metab 1994;14(suppl 1):S115-S120.
17. Wyper DJ, Hunter R, Patterson J, Goodwin G, McCulloch J. A split-dose technique for measuring changes in cerebral blood flow patterns [Abstract]. J Cereb Blood Flow Metab 1991;11(suppl):S449.
18. Dormehl IC, Redelinghuys IF, Hugo N, Oliver D, Pilloy W. The baboon model under anaesthesia for in vivo cerebral blood flow studies using SPECT techniques. J Med Prim 1992;21:270-274.
19. 99mTc-HMPAO and SPECT. Nucl Med Commun 1995;14:573-577.
20. 123I(IMP). Nucl Med Biol 1995;22:373-378.
21. Oliver DW, Dormehl IC, Redelinghuys IF, Hugo N, Beverley G. Drug effects on cerebral blood flow in the baboon model: acetazolamide and nimodipine. Nuklearmedizin 1993;32:292-298.
22. Moretti JL, Caglar M, Weinmann P. Cerebral perfusion imaging tracers for SPECT: which one to choose? J Nucl Med 1995;36:359-363.
23. 123I-IMP, Tc-99m-HM-PAO and Tc-99m-ECD: measurements of temporal changes in arterial and jugular venous radioactivity [Abstract]. J Cereb Blood Flow Metab 1991;11(suppl 2):S774.
24. 99mTc-bicisate: comparison with PET measurement and linearization based on permeability-surface area product model. J Cereb Blood Flow Metab 1994;14(suppl 1):S58-S65.
25. Holm S, Madsen PL, Rubin P, Sperling B, Friberg L, Lassen N. Tc-99m HMPAO activation studies: validation of the split-dose, image subtraction approach [Abstract]. J Cereb Blood Flow Metab 1991;11(suppl):S766.
26. Murase K, Tanada S, Inoue T, et al. Kinetic behavior of Tc-99m ECD in the human brain using compartment analysis and dynamic SPECT: comparison with Tc-99m HMPAO. J Nucl Med 1992;33:135-143.
27. Bonte FJ, Devous MD, Reisch JS. The effect of acetazolamide on regional cerebral blood flow in normal human subjects as measured by single photon emission computed tomography. Invest Radiol 1988;23:564-568.
28. 123I]-IMP activated with acetazolamide test. Adv Funct Neuroimag 1989;2:8-15.
29. Gerhardt RE, Knouss RF, Thyrium PT, Luchi RJ, Morris JJ. Quinidine excretion in aciduria and alkaluria [Abstract]. Ann Intern Med 1969;71:927.
30. Goodman LS, Gilman AG. In: Gillman AG, Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics, 8th Ed. New York: Pergamon Press; 1990: 716-717.
31. Vorstrup S. Tomographic cerebral blood flow measurements in patients with ischemic cerebrovascular disease and evaluation of the vasodilatory capacity by the acetazolamide test. Acta Neurol Scand 1988;77(suppl 144):1-48.
32. 99mTc-bicisate in the human brain after intracarotid injection. J Cereb Blood Flow Metab 1994; 14(suppl):S19-S27.
33. McGalden TA, Nath RG. Cerebrovascular autoregulation is resistant to calcium channel blockade with nimodipine. Experientia 1989;45:305-306.
34. Haws CW, Heistad DD. Effects of nimodipine on cerebral vasoconstrictor responses [Abstract]. Am J Phys 1984;247:H170.
35. Sahlin C, Brismar J, Delgado T, Owman C, Salford LG, Svengaard NA. Cerebrovascular and metabolic changes during the delayed vasospasm following experimental subarachnoid hemorrhage in baboons, and treatment with a calcium antagonist. Brain Res 1987:403-413.